| |  i:0#.f|aaccmembershipprovider|164275 | 5/14/2013 12:41 PM | Molecular Pathology and Genetics | |  | | | | | | | May 2013 | 2013 | Patricia M. Jones, PhD, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Jones.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 4/30/2013 2:15 PM | Special Populations | |  | | | | | | | April 2013 | 2013 | Callum G Fraser, PhD & William (Bill) A Bartlett, PhD, FRCPath | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/fraser-bartlett.aspx# | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 4/16/2013 2:17 PM | Case Study; Diabetes/Endocrinology | |  | | | | | | | April 2013 | 2013 | William E. Winter, MD; Roger L. Bertholf, Ph.D. | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/WinterBertholf.aspx# | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 4/2/2013 2:52 PM | Case Study; TDM/Toxicology | |  | http://oxywatchdog.com/2010/11/pill-abuse-among-teens-rampant-in-california-bay-area/ | http://www.heroinprevention.com/linked/content%20for%20website.pdf | | | | | April 2013 | 2013 | William E. Winter, MD; Lindsay Bazydlo, PhD, and Neil S. Harris, MD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/WinterHarrisBazydlo.aspx# | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 3/19/2013 3:55 PM | Special Populations; New/Other Disease Markers | |  | | | | | | | March 2013 | 2013 | Michael J. Bennett Ph.D., FRCPath, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Bennett.aspx# | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 3/5/2013 9:32 AM | Case Study; Molecular Pathology and Genetics | | | | | | | | | March 2013 | 2013 | William E. Winter, MD; Lindsay Bazydlo, PhD, and Neil S. Harris, MD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/WinterHarrisBazydlo.aspx# | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 2/19/2013 11:55 AM | Instrumentation/Technology; Management/Medical Informatics | |  | | | | | | | February 2013 | 2013 | Christine Snozek, PhD, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Christine-Snozek.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 2/5/2013 4:45 PM | Case Study; Instrumentation/Technology | |  | | | | | | | February 2013 | 2013 | Sutirtha Chakraborty, MD & William Winter, MD, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/WinterChakraborty.aspx | 1 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 1/22/2013 2:01 PM | CVD/Markers/Risk Factors | |  | | | | | | | January 2013 | 2013 | Verena Gounden, MBChB, FCP, MMed and Zhen Zhao, PhD, DABCC | http://http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Gounden-Zhao.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 1/8/2013 2:05 PM | POC Testing | |  | | | | | | | January 2013 | 2013 | Nichole Korpi-Steiner, PhD, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/korpi-steiner.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 12/26/2012 4:11 PM | Management/Medical Informatics | |  | | | | | | | December 2012 | 2012 | Stanley F. Lo, Ph.D., DABCC, FACB | http://www.aacc.org/members/sycl/mentor/past_mentors/2012/May/Pages/default.aspx# | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 12/11/2012 11:48 AM | Management/Medical Informatics | |  | | | | | | | December 2012 | 2012 | Douglas F. Stickle, PhD, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Stickle.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 11/27/2012 10:19 AM | Diabetes/Endocrinology | |  | | | | | | | November 2012 | 2012 | William Winter, MD, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Winter.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 11/13/2012 1:34 PM | CVD/Markers/Risk Factors | |  | | | | | | | November 2012 | 2012 | James H. Nichols, PhD, DABCC, FACB | http://www.aacc.org/members/divisions/cpoct/biographies/Pages/nichols.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 10/31/2012 12:26 PM | Case Study; Renal/GI/Hepatic | | | | | | | | | October 2012 | 2012 | Dr. Sutirtha Chakraborty, MD and Dr. William Winter, MD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/WinterChakraborty.aspx | 3 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 10/16/2012 10:06 AM | Diabetes/Endocrinology | | | | | | | | | October 2012 | 2012 | William E. Winter, MD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Winter.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 10/2/2012 10:21 AM | Management/Medical Informatics | | | | | | | | | October 2012 | 2012 | Patricia M. Jones, PhD, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Jones.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 9/25/2012 9:29 AM | Clinical Translational Science/Proteomics; Instrumentation/Technology | |  | | | | | | | September 2012 | 2012 | Christopher Doern Ph.D | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Doern.aspx# | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 9/18/2012 9:45 AM | Case Study; Renal/GI/Hepatic | | | | | | | | | September 2012 | 2012 | Dr Sutirtha Chakraborty, MD and Dr William Winter, MD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/WinterChakraborty.aspx | 2 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 9/11/2012 9:50 AM | Renal/GI/Hepatic | |  | | | | | | | September 2012 | 2012 | Ioannis Papassotiriou, PhD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Papassotiriou.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|164275 | 9/4/2012 10:04 AM | CVD/Markers/Risk Factors | |  | | | | | | | September 2012 | 2012 | Niel Harris, MD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Harris.aspx | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 8/28/2012 9:58 AM | Management/Medical Informatics | |  | | | | | | | August 2012 | 2012 | M. Laura Parnas, PhD, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Parnas.aspx# | 1 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 8/21/2012 10:27 AM | Management/Medical Informatics | |  | | | | | | 1. Hoffmann RG, Waid ME. The “average of normals” method of quality control. Am J Clin Pathol 1965;43:134-41.
2. Cembrowski GS, Chandler EP, Westgard JO. Assessment of “Average of Normals” Quality Control Procedures and Guidelines for Implementation. Am J Clin Pathol 1984; 81: 492-9
| August 2012 | 2012 | Mark Cervinski, PhD, DABCC | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Cervinski.aspx# | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 8/14/2012 9:56 AM | Diabetes/Endocrinology; Case Study | |  | | | | | | | August 2012 | 2012 | William E. Winter, MD, Lindsay Bazydlo, PhD, Neil S. Harris, MD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/WinterHarris.aspx# | 2 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 8/7/2012 10:23 AM | Diabetes/Endocrinology; Case Study | | | | | | | | [1] Alonso N, Granada ML, Lucas A, Salinas I, Reverter J, Oriol A, Sanmarti A.
Evaluation of two replacement regimens in primary adrenal insufficiency patients. effect on clinical symptoms, health-related quality of life and biochemical parameters. J Endocrinol Invest. 2004 May;27(5):449-54.
[2] Jeffcoate W. Assessment of corticosteroid replacement therapy in adults with adrenal insufficiency. Ann Clin Biochem. 1999 Mar;36 ( Pt 2):151-7.
[3] Burch WM. Urine free-cortisol determination. A useful tool in the management of chronic hypoadrenal states. JAMA. 1982 Apr 9;247(14):2002-4.
| August 2012 | 2012 | William E. Winter, MD and Roger L. Bertholf, PhD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/winterbertholf.aspx# | 1 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 7/31/2012 5:49 PM | Management/Medical Informatics | | | | | | | | | July 2012 | 2012 | Patti Jones, PhD, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/jones.aspx# | 1 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 7/24/2012 11:17 AM | Case Study; Instrumentation/Technology | | | | | | | | | July 2012 | 2012 | William E. Winter, MD and Roger L. Bertholf, PhD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/winterbertholf.aspx# | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 7/18/2012 5:35 PM | Government Affairs/Patient Safety | |  | | | | | | References
1. Stark L. Behind Closed Doors, IRBs and the Making of Ethical Research, University of Chicago Press, Chicago, 2012.
2. Keiger D., De Pasquale S. Trials & tribulation, Johns Hopkins Magazine, vol. 54, No. 1, February 2002.
3. London A., Kimmelman J., Carlisle B. Rethinking research ethics: The case of postmarketing trials, Science 336, 544-45, 2012. | July 2012 | 2012 | Doug Dix, PhD, DABCC, FACB | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/dix.aspx# | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 7/10/2012 9:48 AM | Special Populations; TDM/Toxicology | |  | MSN coverage of positive drug tests in newborns | Local North Carolina news coverage | | | | | July 2012 | 2012 | Steve Cotten, PhD and Catherine Hammett-Stabler, PhD | http://www.aacc.org/resourcecenters/AACCBlogs/bios/Pages/Cotton_Hammett-Stabler.aspx# | 2 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 7/2/2012 3:39 PM | | |  | | | | | | | July 2012 | 2012 | Dina Greene, PhD, DABCC and Amy Pyle, PhD, DABCC | Dina Greene, PhD, DABCC and Amy Pyle, PhD, DABCC | 1 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 6/26/2012 9:46 AM | Instrumentation/Technology | |  | | | | | | References: 1. Miller, WG and Meyers, GL., NACB Blog (4/12/2011)
| June 2012 | 2012 | Pamela Steele, PhD | Pamela Steele, PhD | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|84458 | 6/19/2012 9:02 AM | Management/Medical Informatics | |  | | | | | | | June 2012 | 2012 | Pamela Banning, MT(ASCP)cm, PMP | Pamela Banning, MT(ASCP)cm, PMP | 1 | | Approved |
| | i:0#.f|aaccmembershipprovider|137756 | 6/12/2012 8:58 AM | Case Study; Diabetes/Endocrinology | | | | | | | | | June 2012 | 2012 | William E. Winter, MD, and Roger L. Bertholf, PhD | William E. Winter, MD, and Roger L. Bertholf, PhD | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|137756 | 6/5/2012 8:39 AM | POC Testing; Instrumentation/Technology | |  | | | | | | References
1. Crit Care Med 2003:31:S715-20. Blood conservation in the intensive care unit.
2. Arch Intern Med 2011;171:1646-53. Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction.
3. Heart and Lung 2010;39:217-25. Anemia and blood transfusion practices in the critically ill: A prospective cohort review.
| June 2012 | 2012 | Brad S. Karon, MD, PhD, FACB | Brad S. Karon, MD, PhD, FACB | 2 | | Approved |
| | i:0#.f|aaccmembershipprovider|137756 | 5/29/2012 9:40 AM | Management/Medical Informatics | |  | | | | | | 
| May 2012 | 2012 | Gregory J. Buffone, PhD | Gregory J. Buffone, PhD | 1 | | Approved |
| | i:0#.f|aaccmembershipprovider|137756 | 5/22/2012 9:20 AM | Instrumentation/Technology | |  | | | | | | | May 2012 | 2012 | Larry J. Kricka DPhil, FACB, CSci, CChem, FRSC, FRCPath | Larry J. Kricka DPhil, FACB, CSci, CChem, FRSC, FRCPath | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|137756 | 5/15/2012 9:10 AM | Renal/GI/Hepatic | |  | | | | | | References
1. Myers, et al, Clin Chem 2006:52, 5-18.
2. Greenberg, et al, Clin Chem 2011:58, 391-401.
3. Levey, et al, Clin Chem 2007:53, 766-772.
4. National Kidney Disease Education Program, Working Group meeting 2011.
5. Levey, et al, Ann Intern Med 2009:150, 604-612.
6. National Kidney Disease Education Program: Laboratory Evaluation.
7. National Kidney Disease Education Program: CKD and Drug Dosing: Information for Providers.
8. Schwartz, et al, J Am Soc Nephrol 2009:20, 629-637.
9. Grubb, et al, Clin Chem Lab Med 2010:48, 1619-1621.
| May 2012 | 2012 | Jack Zakowski, PhD, FACB | Jack Zakowski, PhD, FACB | 0 | | Approved |
| | i:0#.f|aaccmembershipprovider|137756 | 5/8/2012 11:59 AM | Special Populations | |  | | | | | | | May 2012 | 2012 | Khosrow Adeli, PhD, FCACB, FACB, DABCC | Khosrow Adeli, PhD, FCACB, FACB, DABCC | 4 | | Approved |
| | i:0#.f|aaccmembershipprovider|137756 | 5/1/2012 9:08 AM | CVD/Markers/Risk Factors | |  | | | | | | References
1. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746-56.
2. Hoofnagle AN, Wu M, Gosmanova AK, Becker JO, Wijsman EM, Brunzell JD, et al. Low Clusterin Levels in High-Density Lipoprotein Associate With Insulin Resistance, Obesity, and Dyslipoproteinemia. Arterioscler Thromb Vasc Biol. 2010;30:2528-34.
3. Green PS, Vaisar T, Pennathur S, Kulstad JJ, Moore AB, Marcovina S, et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation. 2008;118:1259-67.
4. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics I: Mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2005;5:551-65.
5. Peterson MM, Mack JL, Hall PR, Alsup AA, Alexander SM, Sully EK, et al. Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection. Cell Host Microbe. 2008;4:555-66.
| May 2012 | 2012 | Andrew Hoofnagle, MD, PhD | Andrew Hoofnagle, MD, PhD | 2 | | Approved |
| | AACC\bgarman | 4/24/2012 8:25 AM | Case Study | | | | | | | | | April 2012 | 2012 | William E. Winter, MD, and Roger L. Bertholf, PhD | William E. Winter, MD, and Roger L. Bertholf, PhD | 6 | | Approved |
| | AACC\bgarman | 4/17/2012 8:29 AM | Instrumentation/Technology; Cancer and Tumor Markers; Diabetes/Endocrinology | |  | | | | | | References
1. Algeciras-Schimnich A, Lasho MA, Ness KM, Cheryk LA, Grebe SK. Thyroid 2011; 21(7):813-4.
2. Spencer C, Petrovic I, Fatemi S. J Clin Endocrinol Metab. 2011 May;96(5):1283-91.
3. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Clin Chem. 2008;54(11):1796-804.
 | April 2012 | 2012 | Alicia Algeciras-Schimnich, PhD | Alicia Algeciras-Schimnich, PhD | 0 | | Approved |
| | AACC\bgarman | 4/10/2012 8:28 AM | Nutrition | |  | | | | | | | April 2012 | 2012 | Kenneth Hoekstra, PhD, HCLD, FACB | Kenneth Hoekstra, PhD, HCLD, FACB | 2 | | Approved |
| | AACC\bgarman | 4/3/2012 8:31 AM | Diabetes/Endocrinology | | | | | | | | | April 2012 | 2012 | William E. Winter, MD | William E. Winter, MD | 0 | | Approved |
| | AACC\bgarman | 3/27/2012 9:34 AM | | |  | | | | | | | March 2012 | 2012 | Christopher McCudden, PhD, DABCC, FACB | Christopher McCudden, PhD, DABCC, FACB | 0 | | Approved |
| | AACC\bgarman | 3/20/2012 9:21 AM | TDM/Toxicology | |  | | | | | | References 1. Baselt, RC. Disposition of Toxic Drugs and Chemicals in Man. Seventh Edition. 2004. Biomedical Publications, Foster City, CA.
| March 2012 | 2012 | Roger L. Bertholf, PhD, and William E. Winter, MD | Roger L. Bertholf, PhD, and William E. Winter, MD | 0 | | Approved |
| | AACC\bgarman | 3/13/2012 8:22 AM | Management/Medical Informatics | |  | | | | | | References:
1. Wians, FH. To test or not to test? Opening Pandora’s Box. Lab Medicine. 2004; 35:707.
2. Ritchie, JC. NACBlog Is it Time to Remove the Stigma of LDT from Body Fluid Chemistry Assays? July 26, 2011
3. Clinical and Laboratory Standards Institute: Analysis of Body Fluids in Clinical Chemistry; Approved Guideline. Clinical and Laboratory Standards Institute, Wayne, PA, 2007, CLSI document C49-A (ISBN 1-56238-638-7)
4. Chemistry and Toxicology CAP checklist. 2011
| March 2012 | 2012 | Darci Block, PhD, DABCC | Darci Block, PhD, DABCC | 0 | | Approved |
| | AACC\bgarman | 3/6/2012 8:29 AM | Instrumentation/Technology | |  | | | | | | References:
1. Chace D, Mass spectrometry in the clinical laboratory. Chemical reviews, 2001. 101(2): p. 445-772.
2. Strathmann FG and Hoofnagle AN, Current and future applications of mass spectrometry to the clinical laboratory. Am J Clin Pathol, 2011. 136(4): p. 609-16.
Conference
September 6-7, 2012
Chicago, IL
| March 2012 | 2012 | Frederick G. Strathmann, PhD, DABCC | Frederick G. Strathmann, PhD, DABCC | 5 | | Approved |
| | AACC\bgarman | 2/28/2012 8:28 AM | Instrumentation/Technology; Molecular Pathology and Genetics | |  | | | | | | References:
1. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). Journal of the American College of Cardiology 2010;55:2804-12.
2. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proceedings of the National Academy of Sciences of the United States of America 2004;101:4180-5.
3. Nissen SE. Pharmacogenomics and clopidogrel: irrational exuberance? JAMA 2011;306:2727-8.
4. Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704-14.
5. Topol EJ, Teirstein PS, Price M, et al. 2011.
NACB Laboratory Medicine Practice Guideline on Pharmacogenetics
| February 2012 | 2012 | Linnea M. Baudhuin, PhD, DABMG | Linnea M. Baudhuin, PhD, DABMG | 0 | | Approved |
| | AACC\bgarman | 2/21/2012 8:44 AM | TDM/Toxicology | |  | | | | | | References:
- Garg U, Ferguson AM. Alternate specimens for drugs-of-abuse testing: preanalytical and interpretative considerations. In Clinical Toxicology Testing: A Guide for laboratory Professionals 2012. Eds M Barbarajean, MG Bissell, TC Kwong, AHB Wu, CAP Press, pp 71-80.
- Lo Muzio L, Falaschini S, Rappelli G, et al. Saliva as a diagnostic matrix for drug abuse. Int J Immunopathol Pharmacol 2005;18:567-73.
- Gambelunghe C, Rossi R, Ferranti C, Bacci M. Hair analysis by GC/MS/MS to verify abuse of drugs. J Appl Toxicol 2005;25:205-11.
- Dolan K, Rouen D, Kimber J. An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug Alcohol Rev 2004;23:213-7.
| February 2012 | 2012 | Uttam Garg, PhD, DABCC, DABFT, FACB | Uttam Garg, PhD, DABCC, DABFT, FACB | 1 | | Approved |
| | AACC\bgarman | 2/14/2012 8:25 AM | Instrumentation/Technology; Special Populations | |  | | | | | | | February 2012 | 2012 | Donald H. Chace, PhD, MSFS, FACB | Donald H. Chace, PhD, MSFS, FACB | 14 | | Approved |
| | AACC\bgarman | 2/7/2012 8:51 AM | Management/Medical Informatics; Government Affairs/Patient Safety | | | | | | | | | February 2012 | 2012 | Gregory J. Buffone, PhD | Gregory J. Buffone, PhD | 1 | | Approved |
| | AACC\bgarman | 1/31/2012 8:28 AM | Instrumentation/Technology; POC Testing | | | | | | | | References
1. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol. 2005;27:81-90.
2. Hartert H. [Thrombelastography, a method for physical analysis of blood coagulation.] Z Gesamte Exp Med 1951;117:189-203.
3. Kitchen DP, Kitchen S, Jennings I, Woods T, Walker I. Quality assurance and quality control of thromboelastography and rotational thromboelastometry: the UK NEQAS for blood coagulation experience. Semin Thromb Hemost 2010;36:757-63.
4. Chitlur M, Lusher J. Standardization of thromboelastography: values and challenges. Semin Thromb Hemost 2010;36:701-11.
| January 2012 | 2012 | Douglas F. Stickle, PhD, DABCC, FACB | Douglas F. Stickle, PhD, DABCC, FACB | 5 | | Approved |
| | AACC\bgarman | 1/24/2012 8:28 AM | Molecular Pathology and Genetics | |  | | | | | | 
| January 2012 | 2012 | Patti Jones, PhD, and Jason Y. Park, MD | Patti Jones, PhD, and Jason Y. Park, MD | 2 | | Approved |
| | AACC\bgarman | 1/17/2012 10:12 AM | Case Study | | | | | | | | References
[1] Luten M, Roerdinkholder-Stoelwinder B, Bost HJ, Bosman GJ.
Survival of the fittest?--survival of stored red blood cells after transfusion. Cell Mol Biol (Noisy-le-grand). 2004 Mar;50(2):197-203.
[2] Spencer DH, Grossman BJ, Scott MG. Red cell transfusion decreases hemoglobin A1c in patients with diabetes. Clin Chem. 2011 Feb;57(2):344-6.
| January 2012 | 2012 | William E. Winter, MD, and Roger Bertholf, PhD | William E. Winter, MD, and Roger Bertholf, PhD | 3 | | Approved |
| | AACC\bgarman | 1/10/2012 9:36 AM | CVD/Markers/Risk Factors | | | | | | | | References
1. Greenland P, Knoll MD, Stamler J, et al. Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events. JAMA. 2003;290:891-7.
2. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ.Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease. JAMA. 2003;290:898-904.
| January 2012 | 2012 | William E. Winter, MD | William E. Winter, MD | 2 | | Approved |
| | AACC\bgarman | 1/3/2012 9:00 AM | Diabetes/Endocrinology | |  | | | | | | | January 2012 | 2012 | Julie Rosser, DO, and Ronald Whitley, PhD | Julie Rosser, DO, and Ronald Whitley, PhD | 0 | | Approved |
| | AACC\bgarman | 12/29/2011 8:20 AM | | | | | | | | | | December 2011 | 2011 | Patricia Jones, PhD, DABCC, FACB | Patricia Jones, PhD, DABCC, FACB | 1 | | Approved |
| | AACC\bgarman | 12/20/2011 8:26 AM | Case Study | | | | | | | | Reference
1. Ermensa AAM, Vlasveldb LT, Lindemansc J. Significance of elevated cobalamin (vitamin B12) levels in blood. Clinical Biochemistry 36 (2003) 585–590
| December 2011 | 2011 | William E. Winter, MD, DABCC, FACB | William E. Winter, MD, DABCC, FACB | 0 | | Approved |
| | AACC\bgarman | 12/13/2011 9:22 AM | Diabetes/Endocrinology; Case Study | |  | | | | | | 1. Velloso LA, Kämpe O, Hallberg A, Christmanson L, Betsholtz C, Karlsson FA. Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest. 1993 May;91(5):2084-90.
2. Scherbaum WA, Trischler G, Pfeiffer EF. Non-human primate pancreas as a substrate for the detection of islet-cell antibodies in human sera. Diabetes Res Clin Pract. 1989 Jun 20;7(1):1-5.
3. Bergerot I, Souchier C, Thivolet C. Heterogeneity of islet cell cytoplasmic antibodies and autoantibodies to glutamate decarboxylase in relatives of patients with type 1 (insulin-dependent) diabetes. C R Acad Sci III. 1993 Nov;316(11):1368-73.
4. 4. Colman PG, Nayak RC, Campbell IL, Eisenbarth GS. Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid extracts Diabetes. 1988 May;37(5):645-52.
5. Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem. 2011 Feb;57(2):168-75.
| December 2011 | 2011 | William E. Winter, MD, and Patti Jones, PhD | William E. Winter, MD, and Patti Jones, PhD | 0 | | Approved |
| | AACC\bgarman | 12/6/2011 9:22 AM | Case Study | | | | | | | | Additional Contributors to this blog post:
Neil S. Harris, MD, Associate Professor of Pathology
Lindsay Bazydlo, PhD, Assistant Professor Pathology
| December 2011 | 2011 | William E. Winter, MD, DABCC, FACB | William E. Winter, MD, DABCC, FACB | 4 | | Approved |
| | AACC\bgarman | 11/29/2011 8:42 AM | Government Affairs/Patient Safety | |  | | | | | | | November 2011 | 2011 | James Faix, MD | James Faix, MD | 0 | | Approved |
| | AACC\bgarman | 11/22/2011 6:57 AM | Cancer and Tumor Markers | |  | | | | | | References
1. Johansson J-E, Andrén O, Andersson S-O, Dickman PW, Holmberg L, Magnuson A, et al. Natural History of Early, Localized Prostate Cancer. JAMA: The Journal of the American Medical Association 2004;291:2713-2719.
2. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality Results from a Randomized Prostate-Cancer Screening Trial. New England Journal of Medicine 2009;360:1310-1319.
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine 2009;360:1320-1328.
4. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, et al. Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. Journal of the National Cancer Institute 2008;100:1144-1154.
| November 2011 | 2011 | D. Robert Dufour, MD, FACB | D. Robert Dufour, MD, FACB | 3 | | Approved |
| | AACC\bgarman | 11/15/2011 9:16 AM | Diabetes/Endocrinology; Instrumentation/Technology | |  | | | | | | | November 2011 | 2011 | Steven Soldin, PhD, DABCC, FACB | Steven Soldin, PhD, DABCC, FACB | 2 | | Approved |
| | AACC\bgarman | 11/8/2011 8:35 AM | Diabetes/Endocrinology; POC Testing | |  | | | | | | References
1. NACB. Evidenced-based Practice for Point-of-Care Testing. NACB Practice Guidelines. 2006.
2. When the test really counts. Consumer Reports 2003 February: 45-50.
3. Cervinski MA, Lockwood CM, Ferguson AM, Odem RR, Stenman UH, Alfthan H, et al. Qualitative point-of-care and over-the-counter urine hCG devices differentially detect the hCG variants of early pregnancy. Clin Chim Acta. 2009;406(1-2):81–85. 4. Sigel CS, Grenache DG. Detection of unexpected isoforms of human chorionic gonadotropin by qualitative tests. Clin Chem. 2007;53(5):989–990.
5. Gronowski AM, Cervinski M, Stenman U-H, Woodworth A, Ashby L, Scott MG. False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment. Clin Chem. 2009;55(7):1389–1394.
6. Greene, D: What could be simpler than a pregnancy test? NACBLOG
| November 2011 | 2011 | David G. Grenache, PhD, DABCC, FACB | David G. Grenache, PhD, DABCC, FACB | 0 | | Approved |
| | AACC\bgarman | 11/1/2011 8:26 AM | Case Study; Diabetes/Endocrinology | | | | | | | | | November 2011 | 2011 | William E. Winter, MD, DABCC, FACB | William E. Winter, MD, DABCC, FACB | 21 | | Approved |
| | AACC\bgarman | 10/25/2011 8:15 AM | Government Affairs/Patient Safety | | | | | | | | | October 2011 | 2011 | Patricia M. Jones, PhD, DABCC, FACB | Patricia M. Jones, PhD, DABCC, FACB | 1 | | Approved |
| | AACC\bgarman | 10/18/2011 8:19 AM | Cancer and Tumor Markers | |  | | | | | | References
1. Kyle RA, Rajkumar SV “Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.” Leukemia. (2009); 23(1):3-9.
2. Fonesca et. al. “International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.” Leukemia. (2009); 23(12):2210-21.
3. Keren, D.F. “Heavy/Light-chain analysis of monoclonal gammopathies. Clin Chem, (2009); 55, 1606-1608.
| October 2011 | 2011 | Joshua Bornhorst, PhD | Joshua Bornhorst, PhD | 1 | | Approved |
| | AACC\bgarman | 10/11/2011 8:05 AM | Molecular Pathology and Genetics | |  | | | | | | References
1) Neumann PJ, Cohen JT, Hammitt JK, et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ. 2010 Dec 28. DOI: 10.1002/hec.1704
2) Direct-To-Consumer Genetic Tests: Misleading Test Results Are Further Complicated by Deceptive Marketing and Other Questionable Practices GAO-10-847T, Jul 22, 2010
| October 2011 | 2011 | K.T. Jerry Yeo, PhD | K.T. Jerry Yeo, PhD | 3 | | Approved |
| | AACC\bgarman | 10/4/2011 8:48 AM | TDM/Toxicology | |  | | | | | | | October 2011 | 2011 | Donald L. Frederick, PhD, DABFT | Donald L. Frederick, PhD, DABFT | 2 | | Approved |
| | AACC\bgarman | 9/27/2011 8:37 AM | Management/Medical Informatics | |  | | | | | |
- Fraser CG. Biological Variation: From Principles to Practice. ASCP Press (2001).
- Strathmann FG, Baird GS, Hoffman NG. Simulations of delta check rule performance to detect specimen mislabeling using historical laboratory data. Clin Chim Acta 412:1973-7 (2011).
| September 2011 | 2011 | Joely Straseski, PhD | Joely Straseski, PhD | 1 | | Approved |
| | AACC\bgarman | 9/20/2011 7:58 AM | Case Study; Special Populations; Molecular Pathology and Genetics | | | | | | | | (1) Schroeder V, Durrer D, Meili E, Schubiger G, Kohler HP. Congenital factor XIII deficiency in Switzerland: from the worldwide first case in 1960 to its molecular characterization in 2005. Swiss Med Wkly. 2007 May 19;137(19-20):272-8.
(2) Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia. 2008 Nov;14(6):1190-200.
(3) Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. Semin Thromb Hemost. 2009 Jun;35(4):426-38.
| September 2011 | 2011 | William Winter, MD | William Winter, MD | 1 | | Approved |
| | AACC\bgarman | 9/13/2011 9:10 AM | Diabetes/Endocrinology | |  | | | | | | 1. Gronowski AM, Cervinski M, Stenman UH, et al. False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment. Clinical Chemistry 2009:55;1389–1394.
2. Grenache DG, Greene DN, Dighe AS, et al. Falsely decreased human chorionic gonadotropin (hCG) results due to increased concentrations of the free beta subunit and the beta core fragment in quantitative hCG assays. Clinical Chemistry 2010:56;1839–1844.
| September 2011 | 2011 | Dina Greene, PhD | Dina Greene, PhD | 1 | | Approved |
| | AACC\bgarman | 9/7/2011 8:12 AM | Case Study; Diabetes/Endocrinology | | | | | | | | | September 2011 | 2011 | William Winter, MD | William Winter, MD | 10 | | Approved |
| | AACC\bgarman | 8/30/2011 8:19 AM | Diabetes/Endocrinology | | | | | | | | References
1. American Diabetes Association. Standards of Medical Care in Diabetes—2011.
Diabetes Care 2011; 34, Supplement 1: S11-S61.
2. Sacks DB et al. Position Statement Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care 2011;34:1419-1423.
3. American College of Obstetricians and Gynecologists. Gestational Diabetes. ACOG Practice Bulletin Clinical Guidelines for Obstetrician-Gynecologists. Number 30, September 2001.
4. Coustan DR et al. Should the fifty-gram, one-hour plasma glucose screening test for gestational diabetes be administered in the fasting or fed state? Am J Obstet Gynecol 1986 May;154(5):1031-5.
5. Lewis GF et al. Prior feeding alters the response to the 50-g glucose challenge test in pregnancy. The Staub-Traugott effect revisited. Diabetes Care. 1993 Dec;16(12):1551-6.
6. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. World Health Organization, Dept Noncommunicable Disease Surveillance, Geneva, 1999.
| August 2011 | 2011 | Douglas Stickle, PhD | Douglas Stickle, PhD | 6 | | Approved |
| | AACC\bgarman | 8/23/2011 8:06 AM | Cancer and Tumor Markers | | | | | | | | References
1. Fraser CG. Fecal occult blood tests. Life savers or outdated colorectal screening tools? Clin Lab News 2011:37(3):8-10. swww.aacc.org/publications/cln/2011/march/Pages/FecalOccult.aspx
2. AACC Lecture Library. Colon cancer: The role of fecal tests – 2011.
3. Fraser CG. Screening for colorectal neoplasia with faecal tests, Lancet Oncol 2011;12:516-7.
4. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244–55.
5. Fraser CG, Mathew CM, McKay K, Carey FA, Steele RJ. Automated immunochemical quantitation of haemoglobin in faeces collected on cards for screening for colorectal cancer. Gut 2008;57:1256-60.
6. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 2010;105:2457-64.
7. Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, et al. Test performance of fecal occult blood testing and sigmoidoscopy compared with colonoscopy screening for colorectal advanced adenoma. Cancer Prev Res 2011 Jul 12. Epub ahead of print
8. Chen L-S, Yen A M-F, Chiu S H-Y, Liao C-S, Chen H-H. Baseline immunochemical faecal occult blood test (iFOBT) concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 2011;12:551-8.
| August 2011 | 2011 | Callum Fraser, PhD | Callum Fraser, PhD | 0 | | Approved |
| | AACC\bgarman | 8/16/2011 8:06 AM | TDM/Toxicology | |  | | | | | | | August 2011 | 2011 | Gwen McMillin, PhD | Gwen McMillin, PhD | 0 | | Approved |
| | AACC\bgarman | 8/9/2011 9:24 AM | Special Populations | | | | | | | | References
1. Chemical & Engineering News, 17 January 2011, pp. 13-17
2. Bioanalysis 2010;2(8):1343-4.
3. Bioanalysis 2010;2(11):1781.
4. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr 2001;131(5):1631S-6S.
5. Egier DA, Keys JL, Hall SK, McQueen MJ. Measurement of hemoglobin A1c from filter papers for population-based studies. Clin Chem 2011;57(4):577-85.
6. Deniff P, Spooner S. The effect of hematocrit on assay bias when using dried blood spots samples for the quantitative bioanalysis of drugs. European Bioanlysis Forum Workshop: Connecting Strategies on Dried Blood Spots, June 17-18, 2010, Brussels, Belgium
7. Meany DL, Clarke W. Opiate DAU screening using dried urine specimens. Clin Chim Acta. 2009;401(1-2):188-9.
| August 2011 | 2011 | Douglas F. Stickle, PhD | Douglas F. Stickle, PhD | 2 | | Approved |
| | AACC\bgarman | 8/2/2011 9:11 AM | Case Study; Diabetes/Endocrinology | | | | | | | | | August 2011 | 2011 | William Winter, MD | William Winter, MD | 9 | | Approved |
| | AACC\bgarman | 7/26/2011 7:50 AM | Government Affairs/Patient Safety | |  | | | | | | References
1. Clinical and Laboratory Standards Institute. Body Fluid Analysis for Cellular Composition; Approved Guideline. CLSI document H56-A [ISBN 1-56238-614-X]. Clinical and Laboratory Standards Institute, Wayne, PA, 2006
2. Clinical and Laboratory Standards Institute. Analysis of Body Fluids in Clinical Chemistry; Approved Guideline. CLSI document C49-A [ISBN 1-56238-638-7]. Clinical and Laboratory Standards Institute, Wayne, PA, 2007
3. Nontraditional Body Fluid Analysis, Sanford, KW, (2006)
| July 2011 | 2011 | James C. Ritchie, PhD | James C. Ritchie, PhD | 1 | | Approved |
| | AACC\bgarman | 7/19/2011 8:16 AM | Government Affairs/Patient Safety | | | | | | | | | July 2011 | 2011 | Patti Jones, PhD, FACB, and Jason Park, MD | Patti Jones, PhD, FACB, and Jason Park, MD | 3 | | Approved |
| | AACC\bgarman | 7/12/2011 8:05 AM | Diabetes/Endocrinology | | | | | | | | * Wherrett DK, Bundy B, Becker DJ, et al: Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet [Epub June 27, 2011]Orban T, Bundy B, Becker DJ, et al: Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: A Randomized Double-Masked Controlled Trial. Lancet [Epub June 28, 2011]
| July 2011 | 2011 | William Winter, MD | William Winter, MD | 0 | | Approved |
| | AACC\bgarman | 7/5/2011 8:32 AM | Case Study | | | | | | | | | July 2011 | 2011 | William Winter, MD | William Winter, MD | 13 | | Approved |
| | AACC\bgarman | 6/28/2011 8:24 AM | Renal/GI/Hepatic; TDM/Toxicology | |  | | | | | | References
1. Myers GL, Miller WG, Coresh J et al. Recommendations for improving serum creatinine measurements: A report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006;52:5-18.
3. Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009;54:33-42.
Additional Reading
Narva AS. Assessment of Kidney Function for Drug Dosing. Clin Chem 2009;55:1069-1611.
Fraser, Callum. Estimating GFR: What’s Wrong with Using Serum Creatinine Alone? NACBLOG January 25, 2011.
Creatinine Calibration: An Inconvenient Truth
Josef Coresh, MD, PhD
AACC Annual Meeting Plenary Session
July 27, 2011 Georgia World Congress Center | June 2011 | 2011 | Angela M. Ferguson, PhD | Angela M. Ferguson, PhD | 0 | | Approved |
| | AACC\bgarman | 6/21/2011 8:40 AM | Management/Medical Informatics | |  | | | | | | | June 2011 | 2011 | Roland Valdes, Jr, PhD | Roland Valdes, Jr, PhD | 0 | | Approved |
| | AACC\bgarman | 6/14/2011 8:32 AM | TDM/Toxicology | |  | | | | | | Additional Reading
Couto JE, Webster L, Romney MC, Leider HL, Linden A. Use of an algorithm applied to urine drug screening to assess adherence to an OxyContin regimen. Journal of Opioid Management 2009;5(6):359-64.
Reisfield GM, Goldberger BA, Crews BO, Pesce AJ, Wilson GR, Teitelbaum SA, Bertholf RL. Ethyl glucuronide, ethyl sufate, and ethanol in urine after sustained exposure to an ethanol-based hand sanitizer. Journal of Analytical Toxicology 2011;35(2):85-91.
Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Annals of Clinical and Laboratory Science 2007;37(4):301-14.
Reisfield GM, Goldberger BA, Bertholf RL. “False positive” and “false negative” test results in clinical urine drug testing. Bioanalysis 2009;1(5):937-52.
| June 2011 | 2011 | Roger L. Bertholf, PhD | Roger L. Bertholf, PhD | 3 | | Approved |
| | AACC\bgarman | 6/7/2011 8:28 AM | Case Study | | | | | | | | | June 2011 | 2011 | William Winter, MD | William Winter, MD | 0 | | Approved |
| | AACC\bgarman | 5/31/2011 8:46 AM | Diabetes/Endocrinology | |  | | | | | | | May 2011 | 2011 | Ravinder Singh, PhD | Ravinder Singh, PhD | 2 | | Approved |
| | AACC\bgarman | 5/24/2011 8:38 AM | Instrumentation/Technology; Management/Medical Informatics | | | | | | | | References
1. Demner-Fushman D, Chapman WW, McDonald CJ. What can natural language processing do for clinical decision support? J Biomed Inform 2009 Oct;42(5):760-72. Epub 2009 Aug 13. (Review)
2. IBM Watson
3. "Dr Watson, We Presume." Science 2011;331:992.
4. Main C, Moxham T, Wyatt JC, Kay J, Anderson R, Stein K. Computerized decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems. Health Technol Assess 2010 Oct;14(48):1-227. (Review)
5. Robertson J, Walkom E, Pearson SA, Hains I, Williamsone M, Newby D. The impact of pharmacy computerised clinical decision support on prescribing, clinical and patient outcomes: a systematic review of the literature. Int J Pharm Pract 2010 Apr;18(2):69-87. (Review)
6. Hemmerling TM. Automated anesthesia. Curr Opin Anaesthesiol 2009 Dec;22(6):757-63. (Review)
7. Stivaros SM, Gledson A, Nenadic G, Zeng XJ, Keane J, Jackson A. Decision support systems for clinical radiological practice -- towards the next generation. Br J Radiol 2010 Nov;83(995):904-14. (Review)
8. Elkin PL, Liebow M, Bauer BA, Chaliki S, Wahner-Roedler D, Bundrick J, Lee M, Brown SH, Froehling D, Bailey K, Famiglietti K, Kim R, Hoffer E, Feldman M, Barnett GO. The introduction of a diagnostic decision support system (DXplain™) into the workflow of a teaching hospital service can decrease the cost of service for diagnostically challenging Diagnostic Related Groups (DRGs). Int J Med Inform 2010 Nov;79(11):772-7. Epub 2010 Oct 14. (Review)
9. "Schooling the Jeopardy! Champ: Far from Elementary." Science 2011;331:999.
10. Baker S. Final Jeopardy: Man vs. Machine and the Quest to Know Everything. Houghton Mifflin Harcourt Publishing, New York, 2011. | May 2011 | 2011 | Douglas F. Stickle, PhD | Douglas F. Stickle, PhD | 1 | | Approved |
| | AACC\bgarman | 5/17/2011 8:35 AM | Diabetes/Endocrinology | |  | | | | | | References
1. Demers LM, Spencer CA. Laboratory support for the diagnosis and monitoring of thyoid disease. Laboratory Medicine Practice Guidelines. NACB vol. 13, 2002.
2. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 2004;291:228-238.3. Mariotti S. Solving the dilemma: what to do as a simple clinician. Endocrine Abstracts 2010;22:S13.4. | May 2011 | 2011 | Martin Kroll, MD, FACB | Martin Kroll, MD, FACB | 2 | | Approved |
| | AACC\bgarman | 5/10/2011 8:15 AM | Diabetes/Endocrinology; POC Testing | | | | | | | | References
1. International Organization for Standardization. In vitro diagnostic test systems-Requirements for blood glucose monitoring systems for self-testing in managing Diabetes Mellitus. Report Number ISO 15197 2003.
2. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.3. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.4. NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.
5. Karon BS, Boyd JC, Klee GG. Glucose meter performance criteria for tight glycemic control estimated by simulation modeling. Clin Chem 2010;56:1091-7. | May 2011 | 2011 | Brad Karon, MD, PhD | Brad Karon, MD, PhD | 5 | | Approved |
| | AACC\bgarman | 4/28/2011 3:21 PM | Diabetes/Endocrinology; Case Study | | | | | | | | | April 2011 | 2011 | William Winter, MD | William Winter, MD | 39 | | Approved |
| | AACC\bgarman | 4/26/2011 9:03 AM | Instrumentation/Technology | | | Mass Spec in Clinical Labs. CLN September 2010 | | | | | | April 2011 | 2011 | Michael Bennett, PhD | Michael Bennett, PhD | 4 | | Approved |
| | AACC\bgarman | 4/19/2011 8:09 AM | Management/Medical Informatics; Instrumentation/Technology | |  | | | | | | | April 2011 | 2011 | Fritz F. Parl, MD, PhD | Fritz F. Parl, MD, PhD | 1 | | Approved |
| | AACC\bgarman | 4/12/2011 8:04 AM | Instrumentation/Technology | |  | | | | | |
References
1. ISO 17511:2003 In vitro diagnostic medical devices -Measurement of quantities in biological samples - Metrological traceability of values assigned to calibrators and control materials, International Organization for Standardization, Geneva, Switzerland, 2003.
2. Vesper HW, Thienpont LM. Traceability in laboratory medicine. Clin Chem 2009;55:1067-1075.
3. Miller WG, Myers GL, Rej R. Why commutability matters. Clin Chem 2006;52:553-4.
4. Vesper HW, Miller WG, Myers GL. Reference materials and commutability. Clin Biochem Rev 2007;28:139-47.
5. Clinical and Laboratory News, December 2010.
6. European Federation of Clinical Chemistry and Laboratory Medicine Newsletter January 2011.
| April 2011 | 2011 | W. Greg Miller, PhD, and Gary L. Myers, PhD | W. Greg Miller, PhD, and Gary L. Myers, PhD | 7 | | Approved |
| | AACC\bgarman | 4/5/2011 8:02 AM | Diabetes/Endocrinology; Case Study | | | Rodriguez, M. Big penalties for unconventional practice. Florida Medical Business, 2009; 9: 6. | | | | | | April 2011 | 2011 | William Winter, MD, DABCC, FACB | William Winter, MD, DABCC, FACB | 11 | | Approved |
| | AACC\bgarman | 3/29/2011 8:01 AM | New/Other Disease Markers ; Immunology/Infectious Disease | |  | | | | | | References
1. Russell JA. Management of sepsis. N Engl J Med. 2006 Oct 19;355(16):1699-713.
2. McGee KA. Procalcitonin: Clinical Utility in Diagnosing Sepsis. Clinical Laboratory News. 2009;35(7).
3. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15.
4. Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Annals of emergency medicine. 2007 Jul;50(1):34-41.
5. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 2007 Mar;7(3):210-7.
6. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006 Jul;34(7):1996-2003.
7. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010 Feb 6;375(9713):463-74.
| March 2011 | 2011 | Alison Woodworth, PhD, DABCC, FACB | Alison Woodworth, PhD, DABCC, FACB | 6 | | Approved |
| | AACC\bgarman | 3/22/2011 8:08 AM | Renal/GI/Hepatic; POC Testing | |  | | | | | |
References
1. Nichols JH, Bartholomew C, Bonzagi A, GarbJL, Jin L. Evaluation of the IRMA TRUpoint and i-STAT creatinine assays. Clin Chim Acta 2007;377(1-2):201-5.
2. Aumatell A, Sharpe D, Reed W. Validation of the StatSensor meter for testing blood before contrast computed tomography studies. Point of Care 2010;9(1):25-31.
3. Skurup A, Kristensen T, Wennecke F. New creatinine sensor for point-of-care testing of creatinine meets the National Kidney Disease Education Program Guidelines. Clin Chem Lab Med 2008;46(1):3-8.
4. National Kidney Disease Education Program (NKDEP). Creatinine Standardization Recommendations. | March 2011 | 2011 | James H. Nichols, PhD, DABCC, FACB | James H. Nichols, PhD, DABCC, FACB | 4 | | Approved |
| | AACC\bgarman | 3/15/2011 8:06 AM | Renal/GI/Hepatic; Special Populations | |  | | | | | |
IFCC Intl Congress Pediatrics May 13-15, 2011 Berlin, Germany
Lo SF: The Lab's Role in Diagnosis of Neonatal Hyperbilirubinemia. CLN 2010; 36.
Additional Reading
Lo SF, Jendrzejczak B, Doumas BT. Bovine serum-based bilirubin calibrators are inappropriate for some diazo methods. Clin Chem 2010;56:869-872.
American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia. Clinical practice guideline: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297-316.
Canadian Paediatric Society, Fetus and newborn Committee. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks’ gestation). Paediatr Child Health 2007;12 (5):1B-12B.
Karon BS, Wickremasinghe AC, Lo SF, Saenger AK, Cook WJ. BiliChek transcutaneous bilirubin meter overestimates serum bilirubin as measured by the Doumas reference method. Clin Biochem 2010;43:1009-1012. | March 2011 | 2011 | Stanley F. Lo, PhD, DABCC, FACB | Stanley F. Lo, PhD, DABCC, FACB | 4 | | Approved |
| | AACC\bgarman | 3/8/2011 8:05 AM | TDM/Toxicology | | | | | | | |
Contemporary Issues in Clinical TDM/Tox
April 29, Chicago, IL
click here
Clinical and Forensic Toxicology News
Click here
Therapeutic Drug Management and Toxicology Division
Click here
Society of Toxicology 50th Anniversary Meeting/Expo
March 6-10, 2011, Washington, DC
References
Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of five synthetic cannabinoids into schedule I. Fed Regist 2010;75:71635-8.
European Monitoring Centre for Drug and Drug Addiction. www.emcdda.europa.eu (Accessed Jan 21, 2011).
Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Brit J Pharmacol 2010;160: 585–93.
Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R, et al. Purchasing 'legal highs' on the Internet--is there consistency in what you get? QJM 2010;103:489–93.
| March 2011 | 2011 | Donald L. Frederick, PhD, DABFT, FACB | Donald L. Frederick, PhD, DABFT, FACB | 2 | | Approved |
| | AACC\bgarman | 3/1/2011 8:26 AM | Management/Medical Informatics | | | | | | | |
References
Outdated Lab Tests
Requiem for a Heavy Weight
| March 2011 | 2011 | Jim Faix, MD | Jim Faix, MD | 39 | | Approved |